← ANALYST RATINGS · TIPRANKS
Kailera Therapeutics, Inc. (KLRA): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $57.00, the highest $57.00, the lowest $57.00. The average is +406.7% from the last price of $11.25.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Reiterated | 30.09.26on TipRanks 11:15 | +4.1%next day −3.6% · 5 days −9.7% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $57.00 | Buy | +406.7% | Reiterated | 29.09.26on TipRanks Sep 30 05:00 | −1.0%next day +4.1% · 5 days −3.4% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $48.00 | Buy | +326.7% | Reiterated | 14.08.26on TipRanks 10:45 | 0.0%next day +3.6% · 5 days −2.9% | ↗ |
| Hardik Parikh★★★★★★★★★★#11483 · hits 28% · avg −12.1% | J.P. Morgan | $30.00 | Buy | +166.7% | Reiterated | 12.08.26on TipRanks Aug 13 10:25 | −1.7%next day −4.0% · 5 days −1.0% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Initiated | 12.05.26on TipRanks 08:25 | −2.6%next day −5.9% · 5 days −11.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Kailera Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.00 at a price of $11.42 (+294.0%); now: $45.00 at $11.25 (+300.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 2 | 3 | 2 |
| Buy | 2 | 2 | 2 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Kailera Therapeutics, Inc.
- CEO: Ronald C. Renaud Jr.
- Employees: 145
- 180 Third Avenue, 4th Floor, Waltham, MA, 02451, US
- www.kailera.com
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 109 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗